OPPORTUNITY-PLUS INVESTMENT FUND
FUNDS
Explore our current portfolio of investment opportunities across various sectors and stages.
The raison d’être of Opportunity-Plus Investment Fund is to provide meaningful opportunities for investment, foster sustainable growth, and drive long-term value creation for our stakeholders.
Opportunity-Plus Investment Fund has worked with these projects since its launch in May 2025.
From 7 years to 7 days...
Nbryo is an Australian agritech pioneer revolutionizing beef and dairy breeding through rapid, scalable embryo transfer technology. By harnessing advanced bio‑digital and robotic platforms, Nbryo compresses seven years of traditional genetic improvement into just seven days—accelerating trait selection like low methane emissions, better growth, and improved welfare. Their mission bridges productivity, sustainability, and animal care, backed by investment from the Bill & Melinda Gates Foundation and others.
Atibuclimab (IC14) — an anti-CD14 antibody...
Implicit Bioscience is a clinical-stage biotech company harnessing the power of its monoclonal antibody, IC14, to modulate CD14—a master regulator of the immune response—offering new hope in treating inflammatory acute and neurodegenerative conditions. Founded in 2005 by leading immunology pioneers including Prof. Ian Frazer, Implicit is developing IC14-driven therapies across fields such as ALS, acute lung injury, and cardiovascular disease. Their innovative pipeline also includes advanced precision medicine tools to visualize and target immune cells, aiming to enhance treatment efficacy and patient outcomes
More Investment Opportunities Coming Soon
We are actively engaged in evaluating additional high-potential investment opportunities that align with our mission of delivering long-term value and impact. Our next fund is currently in development and will be announced shortly.
Stay tuned as we continue to identify and structure new offerings designed to meet the needs of sophisticated investors seeking access to emerging ventures in high-growth sectors.
Subscribe to our newsletter for updates.